Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) Research & Development: 2020-2025

Historic Research & Development for Fulcrum Therapeutics (FULC) over the last 5 years, with Sep 2025 value amounting to $14.3 million.

  • Fulcrum Therapeutics' Research & Development fell 2.34% to $14.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.1 million, marking a year-over-year decrease of 23.52%. This contributed to the annual value of $63.4 million for FY2024, which is 11.72% down from last year.
  • According to the latest figures from Q3 2025, Fulcrum Therapeutics' Research & Development is $14.3 million, which was up 6.65% from $13.4 million recorded in Q2 2025.
  • In the past 5 years, Fulcrum Therapeutics' Research & Development ranged from a high of $25.0 million in Q2 2022 and a low of $11.7 million during Q4 2024.
  • Moreover, its 3-year median value for Research & Development was $17.0 million (2023), whereas its average is $16.3 million.
  • Per our database at Business Quant, Fulcrum Therapeutics' Research & Development soared by 43.97% in 2022 and then crashed by 38.35% in 2024.
  • Over the past 5 years, Fulcrum Therapeutics' Research & Development (Quarterly) stood at $18.9 million in 2021, then dropped by 1.83% to $18.6 million in 2022, then climbed by 2.33% to $19.0 million in 2023, then slumped by 38.35% to $11.7 million in 2024, then dropped by 2.34% to $14.3 million in 2025.
  • Its last three reported values are $14.3 million in Q3 2025, $13.4 million for Q2 2025, and $11.7 million during Q4 2024.